Maravai LifeSciences Holdings, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Tri Link at $119.8 million, 64% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Tri Link at $119.8 million, 64% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
213
|
186
|
259
|
289
|
883
|
799
|
| Operating segments | ||||||
| Tri Link |
145
+14.2%
share 68.1%
|
120
-39.0%
share 64.5%
|
196
-12.6%
share 75.8%
|
225
-72.4%
share 77.8%
|
813
+14.2%
share 92.1%
|
712
share 89.1%
|
| Cygnus |
68
+3.9%
share 31.9%
|
66
+5.0%
share 35.5%
|
63
-2.1%
share 24.2%
|
64
-8.2%
share 22.2%
|
70
+2.2%
share 7.9%
|
68
share 8.6%
|
| Sales mix | ||||||
| Tri Link |
145
+14.2%
share 68.1%
|
120
-39.0%
share 64.5%
|
196
-12.6%
share 75.8%
|
225
-72.4%
share 77.8%
|
813
+14.2%
share 92.1%
|
712
share 89.1%
|
| Cygnus |
68
+3.9%
share 31.9%
|
66
+5.0%
share 35.5%
|
63
-2.1%
share 24.2%
|
64
-8.2%
share 22.2%
|
70
+2.2%
share 7.9%
|
68
share 8.6%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRVI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1823239
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.